Drugs for Color Vision Deficiency (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 42)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Ranibizumab |
Approved |
Phase 4 |
|
347396-82-1 |
459903
|
Synonyms:
347396-82-1
D05697
Lucentis
Lucentis (TN)
ranibizumab
|
Ranibizumab
Ranibizumab (genetical recombination)
Ranibizumab (genetical recombination) (JAN)
Ranibizumab (USAN/INN)
rhuFab V2
|
|
2 |
|
Angiogenesis Inhibitors |
|
Phase 4 |
|
|
|
3 |
|
Angiogenesis Modulating Agents |
|
Phase 4 |
|
|
|
4 |
|
Clemastine |
Approved, Investigational |
Phase 1 |
|
15686-51-8 |
26987
|
Synonyms:
(+)-(2R)-2-(2-(((R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine
(+)-(2R)-2-(2-(((R)-P-chloro-alpha-Methyl-alpha-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine
(+)-(2R)-2-(2-(((R)-P-chloro-a-Methyl-a-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine
(+)-(2R)-2-(2-(((R)-p-chloro-α-methyl-α-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine
(+)-(2R)-2-(2-(((R)-P-chloro-α-methyl-α-phenylbenzyl)oxy)ethyl)-1-methylpyrrolidine
(+)-(2R)-2-[2-[[(R)-p-Chloro-alpha-methyl-alpha-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine
(+)-(2R)-2-[2-[[(R)-P-chloro-alpha-Methyl-alpha-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine
(+)-(2R)-2-[2-[[(R)-P-chloro-a-Methyl-a-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine
(+)-(2R)-2-[2-[[(R)-p-chloro-α-methyl-α-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine
(+)-(2R)-2-[2-[[(R)-P-chloro-α-methyl-α-phenylbenzyl]oxy]ethyl]-1-methylpyrrolidine
(2R)-2-(2-{[(1R)-1-(4-chlorophenyl)-1-phenylethyl]oxy}ethyl)-1-methylpyrrolidine
(2R)-2-[2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl]-1-methylpyrrolidine
(2R)-2-{2-[(1R)-1-(4-chlorophenyl)-1-phenylethoxy]ethyl}-1-methylpyrrolidine
14976-57-9
15686-51-8
2-(2-(1-(4-Chlorophenyl)-1-phenylethoxy)ethyl)-1-methylpyrrolidine
2-(2-(4-Chlor-alpha-methylbenzhydryloxy)ethyl)-1-methylpyrrolidin
2(R)-[2-[(1R)-(4-Chlorophenyl)-1-phenyl-ethoxy]ethyl-1-methylpyrrolidine
AC1L1CAE
AC1Q3N52
BIDD:GT0391
BPBio1_000300
BRD-K30240666-051-05-0
BSPBio_000272
BSPBio_002045
C21H26ClNO
CAS-14976-57-9
CHEBI:3738
CHEMBL1626
CID26987
Clemastina
Clemastina [INN-Spanish]
clemastine
Clemastine
Clemastine [USAN:BAN]
Clemastine fumarate
|
CLEMASTINE FUMARATE
Clemastinum
Clemastinum [INN-Latin]
DB00283
DivK1c_000285
HMS2089I22
HS 592
HS-592
IDI1_000285
KBio1_000285
KBio3_001265
KBioGR_001570
Lopac-C-8903
LS-137531
Meclastin
Meclastine
Mecloprodin
NCGC00015281-01
NCGC00016710-01
NCGC00025168-01
NINDS_000285
Prestwick0_000306
Prestwick1_000306
Prestwick2_000306
Prestwick3_000306
SPBio_000817
SPBio_002491
Spectrum2_000689
Spectrum3_000353
Spectrum4_000955
Spectrum5_001520
Tavegyl
Tavist
Tavist (*Fumarate*)
Tocris-1453
UNII-95QN29S1ID
|
|
5 |
|
Histamine |
Approved, Investigational |
Phase 1 |
|
51-45-6 |
774
|
Synonyms:
1H-Imidazole-4-ethanamine
2-(1H-Imidazol-4-yl)ethanamine
2-(1H-Imidazol-4-yl)ethylamine
2-(1H-Imidazol-5-yl)ethanamine
2-(1H-Imidazol-5-yl)ethylamine
2-(4-Imidazolyl)ethanamine
2-(4-imidazolyl)ethylamine
2-(4-Imidazolyl)ethylamine
2-Imidazol-4-ylethylamine
2-Imidazol-4-yl-ethylamine
4-(2-Aminoethyl)-1H-imidazole
4-(2-Aminoethyl)imidazole
4-imidazoleethylamine
4-Imidazoleethylamine
5-imidazoleethylamine
5-Imidazoleethylamine
beta-aminoethylglyoxaline
beta-Aminoethylglyoxaline
beta-aminoethylimidazole
|
beta-Aminoethylimidazole
beta-Aminothethylglyoxaline
beta-Imidazolyl-4-ethylamine
b-Imidazolyl-4-ethylamine
Ceplene
Dihydrochloride, histamine
Eramin
Ergamine
Ergotidine
Free histamine
Histamine dihydrochloride
Histamine hydrochloride
HSM
Hydrochloride, histamine
L-Histamin base
L-Histamine
Peremin
Theramine
|
|
6 |
|
Anti-Allergic Agents |
|
Phase 1 |
|
|
|
7 |
|
Histamine Antagonists |
|
Phase 1 |
|
|
|
8 |
|
Histamine H1 Antagonists |
|
Phase 1 |
|
|
|
9 |
|
Dermatologic Agents |
|
Phase 1 |
|
|
|
10 |
|
Histamine Phosphate |
|
Phase 1 |
|
51-74-1 |
65513
|
Synonyms:
1H-Imidazole-4-ethanamine, phosphate (1:2)
2-Imidazol-4-ylethylamine orthophosphoric acid (1:2)
4-(2-Aminoethyl)imidazole bis(dihydrogen phosphate)
4-(2-Aminoethyl)imidazole di-acid phosphate
4-2(2-Aminoethyl)Imidazole-Di-Acid Phosphate
51-74-1
53623-99-7
74-56-6
AC1L23E4
CID65513
D04445
DB00667
EINECS 200-118-4
|
H0147
Histamine acid phosphate
Histamine biphosphate
Histamine dihydrogen phosphate
Histamine diphosphate
Histamine phosphate (1:2)
Histamine phosphate (TN)
Histamine phosphate (USP)
Histamine phosphate [USP]
Histamine positive
LS-78569
UNII-QWB37T4WZZ
|
|
11 |
|
Antipruritics |
|
Phase 1 |
|
|
|
12 |
|
Methamphetamine |
Approved, Illicit |
|
|
537-46-2 |
10836
|
Synonyms:
(+ )-methylamphetamine
(+ )-Methylamphetamine
(+)-(s)-deoxyephedrine
(+)-(S)-Deoxyephedrine
(+)-(S)-N-a-Dimethylphenethylamine
(+)-(s)-n-alpha-dimethylphenethylamine
(+)-(S)-N-alpha-Dimethylphenethylamine
(+)-(S)-N-α-dimethylphenethylamine
(+)-2-(N-methylamino)-1-Phenylpropane
(+)-2-(N-Methylamino)-1-phenylpropane
(+)-methamphetamine
(+)-Methamphetamine
(+)-methylamphetamine
(+)-Methylamphetamine
(+)-n,alpha-dimethyl-beta-phenylethylamine
(+)-N,alpha-Dimethyl-beta-phenylethylamine
(+)-n,alpha-dimethylphenethylamine
(+)-N,alpha-Dimethylphenethylamine
(+)-n-methylamphetamine
(+)-N-Methylamphetamine
(2S)-N-methyl-1-phenylpropan-2-amine
(2S)-N-Methyl-1-phenylpropan-2-amine
(AlphaS)-N,a-dimethylbenzeneethanamine
(alphaS)-N,alpha-dimethylbenzeneethanamine
(AlphaS)-N,alpha-dimethylbenzeneethanamine
(AlphaS)-N,α-dimethylbenzeneethanamine
(s)-(+)-deoxyephedrine
(S)-(+)-Deoxyephedrine
(s)-(+)-methamphetamine
(S)-(+)-Methamphetamine
(s)-(+)-n,alpha,dimethylphenethylamine
(S)-(+)-N,alpha,dimethylphenethylamine
(S)-(+)-N,alpha,Dimethylphenethylamine
(s)-methamphetamine
(S)-Methamphetamine
(s)-methylamphetamine
(S)-Methylamphetamine
(S)-N,a-Dimethylbenzeneethanamine
(s)-n,alpha-dimethylbenzeneethanamine
(S)-N,alpha-Dimethylbenzeneethanamine
(s)-n,alpha-dimethylbenzeneethanoamine
(S)-N,alpha-Dimethylbenzeneethanoamine
(S)-N,α-dimethylbenzeneethanamine
(αS)-N,α-dimethylbenzeneethanamine
139-47-9
14611-50-8
1690-86-4
1-Phenyl-2-methylamino-propan
1-Phenyl-2-methylamino-propan [German]
1-Phenyl-2-methylaminopropane
2S-(+)-Methamphetamine
45952-89-4
537-46-2
Abbott brand OF methamphetamine hydrochloride
AC1L1W1Z
AC1Q4SVR
B40
Benzeneethanamine, N,alpha-dimethyl-, (alphaS)- (9CI)
Benzeneethanamine, N,alpha-dimethyl-, (S)- (9CI)
C07164
C10H15N
CHEBI:6809
CHEMBL1201201
CID10836
Crank
Crank [Street Name]
Crystal Meth
Crystal Meth [Street Name]
d-(S)-Methamphetamine
D-(s)-methamphetamine
D-(S)-Methamphetamine
D08187
D-1-Phenyl-2-methylaminopropan
d-1-Phenyl-2-methylaminopropan [German]
d-1-phenyl-2-methylaminopropane
D-1-Phenyl-2-methylaminopropane
DB01577
d-deoxyephedrine
d-Deoxyephedrine
D-deoxyephedrine
D-Deoxyephedrine
d-desoxyephedrine
d-Desoxyephedrine
D-desoxyephedrine
D-Desoxyephedrine
DEA No. 1105
Deoxyephedrine
desohyephedrine
Desoxyephedrine
Desoxyephedrine hydrochloride
|
Desoxyn
Desyphed
Desyphed hydrochloride
Dextromethamphetamine
d-Methamphetamine
D-methamphetamine
D-Methamphetamine
d-Methylamphetamine
D-methylamphetamine
D-Methylamphetamine
d-N,.alpha.-Dimethylphenethylamine
D-n,alpha-dimethylphenethylamine
D-N,alpha-dimethylphenethylamine
D-N,alpha-Dimethylphenethylamine
d-N-methylamphetamine
d-N-Methylamphetamine
D-n-methylamphetamine
D-N-Methylamphetamine
d-phenylisopropylmethylamine
d-Phenylisopropylmethylamine
D-phenylisopropylmethylamine
D-Phenylisopropylmethylamine
EINECS 208-668-7
HSDB 3359
Hydrochloride, methamphetamine
Ice
ICE [Street Name]
Langly brand OF methamphetamine hydrochloride
L-methamphetamine
L-Methamphetamine
LS-103331
Madrine
Metamfetamina
Metamfetamina [inn-spanish]
Metamfetamina [INN-Spanish]
Metamfetamine
Métamfétamine
Metamfetamine (INN)
Metamfetamine [INN]
Metamfetamine-m
Metamfetaminum
Metamfetaminum [inn-latin]
Metamfetaminum [INN-Latin]
Metamfetaminum [Latin]
Metamphetamine
Metanfetamina
Metanfetamina [inn-spanish]
Metanfetamina [INN-Spanish]
Metanfetamina [Spanish]
Meth
Meth (Street Name)
Methamphetamine
METHAMPHETAMINE
Methamphetamine hydrochloride
Methamphetamine, its salts, isomers, and salts of its isomers
Methamphetaminum
Methamphetaminum [inn-latin]
Methamphetaminum [INN-Latin]
Methamphetaminum [JP]
Methyl-.beta.-phenylisopropylamine
Methylamphetamine
Methyl-beta-phenylisopropylamine
Methyl-b-phenylisopropylamine
methyl-β-phenylisopropylamine
Methyl-β-phenylisopropylamine
MolPort-001-794-405
N Methylamphetamine
N-Methyl-1-phenyl-2-propanamine
N-methylamphetamine
N-Methylamphetamine
N-Methyl-beta-phenylisopropylamin
N-methyl-beta-phenylisopropylamin [german]
N-Methyl-beta-phenylisopropylamin [German]
N-methyl-beta-phenylisopropylamine
N-Methyl-beta-phenylisopropylamine
Norodin
NSC 25115
NSC25115
PDSP1_001404
PDSP1_001405
PDSP2_001388
PDSP2_001389
Phenethylamine, N,alpha-dimethyl-, (S)-(+)- (8CI)
S-(+)-methamphetamine
S-(+)-Methamphetamine
Speed
Speed [Street Name]
Stimulex
UNII-44RAL3456C
WLN: 1MY1&1R -D
|
|
13 |
|
Glycerol |
Approved, Investigational |
Early Phase 1 |
|
56-81-5 |
753
|
Synonyms:
1,2,3-propanetriol
1,2,3-Propanetriol
1,2,3-trihydroxypropane
1,2,3-Trihydroxypropane
Bulbold
Cristal
e 422
Emery 916
Glyceol opthalgan
Glycerin
Glycerin, anhydrous
Glycerin,anhydrous
Glycerine
glycérine
Glycerinum
Glyceritol
Glycerol
glycérol
|
Glycerolum
Glycyl alcohol
Glyrol
Glysanin
Glyzerin
Gro
IFP
Incorporation factor
Mackstat H 66
Monoctanoin component D
Oelsuess
Ölsüß
Osmoglyn
Pricerine 9091
Propanetriol
RG-S
Trihydroxypropane
Tryhydroxypropane
|
|
14 |
|
carbamide peroxide |
Approved |
Early Phase 1 |
|
124-43-6 |
|
Synonyms:
|
15 |
|
Dopamine |
Approved |
|
|
51-61-6, 62-31-7 |
681
|
Synonyms:
(3H)-Dopamine
.alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane
.Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)- (9CI)
1,2-Benzenediol, 4-(2-aminoethyl)-, hydrochloride
1,2-Benzenediol, 4-(2-aminoethyl)-, labeled with tritium
153C5321-5FEE-4B0B-8925-F388F0EEEBD1
2-(3,4-dihydroxyphenyl)ethylamine
2-(3,4-Dihydroxyphenyl)ethylamine
2-benzenediol
3,4 Dihydroxyphenethylamine
3,4-dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine
3,4-Dihydroxyphenethylamine hydrochloride
3,4-Dihydroxyphenylethylamine
3-Hydroxtyramine
3-Hydroxytyramine
3-Hydroxytyramine Hydrobromide
3-Hydroxytyramine hydrochloride
4-(2-Aminoethyl)-1,
4-(2-aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-benzenediol
4-(2-Aminoethyl)-1,2-bezenediol
4-(2-Aminoethyl)benzene-1,2-diol
4-(2-aminoethyl)catechol
4-(2-Aminoethyl)catechol
4-(2-aminoethyl)pyrocatechol
4-(2-aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol
4-(2-Aminoethyl)-pyrocatechol
4-(2-Aminoethyl)pyrocatechol hydrochloride
50444-17-2
51-61-6
62-31-7 (HYDROCHLORIDE)
a-(3,4-Dihydroxyphenyl)-b-aminoethane
AC1L19S5
AC1Q54AX
AC1Q54AY
AKOS003790978
alpha-(3,4-Dihydroxyphenyl)-beta-aminoethane
ASL 279
BIDD:ER0506
Biomol-NT_000001
BPBio1_001123
BSPBio_001932
C03758
CHEBI:18243
CHEMBL59
CID681
cMAP_000036
cMAP_000065
D07870
DB00988
Deoxyepinephrine
DivK1c_000780
Dopamin
Dopamina
Dopamina [INN-Spanish]
dopamine
Dopamine
Dopamine (INN)
Dopamine (USAN)(*hydrochloride*)
Dopamine [INN:BAN]
Dopamine hydrochloride
Dopaminum
Dopaminum [INN-Latin]
Dopastat
Dophamine
Dynatra
EINECS 200-110-0
HSDB 3068
Hydrochloride, dopamine
|
Hydroxytyramin
hydroxytyramine
Hydroxytyramine
IDI1_000780
intropin
Intropin
Intropin [*hydrochloride*]
IP 498
KBio1_000780
KBio2_001492
KBio2_002388
KBio2_002484
KBio2_004060
KBio2_004956
KBio2_005052
KBio2_006628
KBio2_007524
KBio2_007620
KBio3_001152
KBio3_002867
KBio3_002962
KBioGR_001129
KBioGR_002388
KBioGR_002484
KBioSS_001492
KBioSS_002393
KBioSS_002491
KW-3-060
L000232
L-DOPAMINE
LDP
Lopac0_000586
Lopac-H-8502
LS-159
Medopa (TN)
m-Hydroxytyramine hydrochloride
MolPort-001-641-000
NCGC00015519-01
NCGC00015519-08
NCGC00096050-01
NCGC00096050-02
NCGC00096050-03
NCGC00096050-04
NCGC00096050-05
nchembio.105-comp9
nchembio.107-comp4
nchembio.284-comp1
nchembio.78-comp16
nchembio.89-comp3
nchembio705-8
nchembio801-comp8
NINDS_000780
NSC 173182
NSC169105
NSC173182
Oprea1_088821
Oxytyramine
Pyrocatechol, 4-(2-aminoethyl)- (8CI)
Pyrocatechol, 4-(2-aminoethyl)-, hydrochloride
Revimine
Revivan
SPBio_001205
Spectrum_001012
SPECTRUM1505155
Spectrum2_001023
Spectrum3_000406
Spectrum4_000525
Spectrum5_000945
ST048774
STK301601
UNII-VTD58H1Z2X
UPCMLD0ENAT5885989:001
|
|
16 |
|
Aripiprazole |
Approved, Investigational |
|
|
129722-12-9 |
60795
|
Synonyms:
||OPC 14597
129722-12-9
24-29-3
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydro-2(1H)-quinolinone
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butoxy)-3,4-dihydrocarbostyril
7-(4-(4-(2,3-Dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone
7-[4-[4-(2,3-Dichlorophenyl)-1-piperazinyl]butoxy]-3,4-dihydrocarbostyril
7-[4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
7-{4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butoxy}-3,4-dihydroquinolin-2(1H)-one
Abilify
Abilify (TN)
Abilify Discmelt
Abilitat
AC-1554
AC1L1TXZ
AC1Q3T38
ALKS-9070
aripiprazol
Aripiprazol
aripiprazole
Aripiprazole
Aripiprazole (JAN/USAN/INN)
Aripiprazole [USAN]
aripiprazolum
Aripiprazolum
Aripirazole
Arpizol
Asprito|
Bio-0004
BMS-337039
Bristol-Myers Squibb brand of aripiprazole
C094645
C12564
C23H27Cl2N3O2
CHEBI:31236
|
CHEMBL1112
CID60795
CPD000466383
D01164
DB01238
Discmelt
FT-0082572
HMS2051I18
HMS2089M20
HMS2093F22
HSDB 7320
KS-1030
L001339
LS-142666
MLS000759517
MLS001165779
MLS001195621
MLS001424078
MolPort-002-885-808
MolPort-003-844-657
NCGC00159510-02
NCGC00159510-03
Opc 14597
OPC 31
OPC-14597
OPC-31
Otsuka brand of aripiprazole
Pripiprazole
S06-0010
SAM001246750
SMR000466383
STK625160
TL8000707
TL80090184
UNII-82VFR53I78
|
|
17 |
|
Melatonin |
Approved, Nutraceutical, Vet_approved |
|
|
73-31-4 |
896
|
Synonyms:
{N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-} acetamide
{N-[2-(5-methoxyindol-3-yl)ethyl]-} acetamide
0E2B08C1-B325-45B1-8939-6F9081EFDFA4
4-ACETAMIDO-4'-ISOTHIO-CYANATOSTILBENE-2,2'-DISULFONIC ACID
5-22-12-00042 (Beilstein Handbook Reference)
5-methoxy-N-acetyltryptamine
5-Methoxy-N-acetyltryptamine
73-31-4
A4039/0172195
AB00053279
AC1L1A9Q
AC1Q4F1W
AC1Q4F1X
Acetamide, {N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-}
Acetamide, {N-[2-(5-methoxyindol-3-yl)ethyl]-}
Acetamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)- (9CI)
Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI)
Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]- (6CI,8CI)
AKOS000276269
BAS 01281092
BIDD:ER0618
Bio-0635
BPBio1_000590
BRD-K97530723-001-07-6
BRN 0205542
BSPBio_000536
BSPBio_003006
C01598
CAS-73-31-4
CCRIS 3472
CHEBI:16796
CHEMBL45
ChemDiv2_003916
CID896
Circadin
D008550
D08170
DB01065
DB08189
DivK1c_000353
EINECS 200-797-7
EU-0100787
HMS1380B22
HMS1569K18
HMS1921E04
HMS2089F09
HMS501B15
HSCI1_000400
HSDB 7509
I05-0076
I10-0345
IDI1_000353
IDI1_002631
IN1244
KBio1_000353
KBio2_000665
KBio2_003233
KBio2_005801
KBio3_002226
KBioGR_000591
KBioSS_000665
L001261
Lopac0_000787
Lopac-M-5250
LS-1623
M 5250
M1105
M-1200
M-1250
M5250_SIGMA
Melapure
Mela-T
Melatol
Melatonex
Melatonex, Melatonin
Melatonin
Melatonin (synth.) standard-grade
Melatonin (synth.) ultra-pure
Melatonina
Melatonina (TN)
Melatonine
|
Mélatonine
Melovine
ML1
MLS000859594
MLS001055382
MLS001240204
MolPort-000-737-883
MT6
N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide
N-(2-(5-Methoxyindol-3-yl)ethyl)-acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]-acetamide
N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-acetamide
N-[2-(5-methoxyindol-3-yl)ethyl]acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]acetamide
N-[2-(5-Methoxyindol-3-yl)ethyl]-acetamide
N-acetyl-5-methoxy-tryptamine
N-Acetyl-5-methoxytryptamine
N-Acetyl-5-methoxy-tryptamine
N-Acetyl-5-methoxy-tryptamine melatonine
Nature'S Harmony
NCGC00015680-01
NCGC00015680-02
NCGC00015680-03
NCGC00015680-06
NCGC00015680-13
NCGC00090727-01
NCGC00090727-02
NCGC00090727-03
NCGC00090727-04
NCGC00090727-05
NCGC00090727-06
NCGC00090727-07
NCGC00090727-08
NCGC00090727-09
NCI60_004378
Night Rest
NINDS_000353
NMR/14327425
NSC 113928
NSC113928
NSC56423
Oprea1_104553
Oprea1_814234
Pineal Hormone
Posidorm
Prestwick_312
Prestwick0_000458
Prestwick1_000458
Prestwick2_000458
Prestwick3_000458
PREVENTION 1 (MELATONIN) (PREVENTION 1)
PREVENTION 2 (MELATONIN)
PREVENTION 3 (MELATONIN)
PREVENTION 4 (MELATONIN)
PREVENTION 5 (MELATONIN)
Regulin
Revital Melatonin
Rx Balance
S1204_Selleck
SDCCGMLS-0065812.P001
SDCCGMLS-0065812.P002
Sleep Right
SMP2_000309
SMR000326666
SPBio_001527
SPBio_002475
Spectrum_000185
SPECTRUM1500690
Spectrum2_001344
Spectrum3_001393
Spectrum4_000066
Spectrum5_001745
STK386880
TNP00300
UNII-JL5DK93RCL
Vivitas
WLN: T56 BMJ D2MV1 GO1
ZINC00057060
|
|
18 |
|
Sympathomimetics |
|
|
|
|
|
19 |
|
Central Nervous System Stimulants |
|
|
|
|
|
20 |
|
Neurotransmitter Uptake Inhibitors |
|
|
|
|
|
21 |
|
Dopamine Uptake Inhibitors |
|
|
|
|
|
22 |
|
Adrenergic Agents |
|
|
|
|
|
23 |
|
Autonomic Agents |
|
|
|
|
|
24 |
|
Peripheral Nervous System Agents |
|
|
|
|
|
25 |
|
4-phenylbutyric acid |
|
Early Phase 1 |
|
|
|
26 |
|
Protective Agents |
|
Early Phase 1 |
|
|
|
27 |
|
Dopamine Agents |
|
|
|
|
|
28 |
|
Neurotransmitter Agents |
|
|
|
|
|
29 |
|
Tranquilizing Agents |
|
|
|
|
|
30 |
|
Central Nervous System Depressants |
|
|
|
|
|
31 |
|
Serotonin 5-HT2 Receptor Antagonists |
|
|
|
|
|
32 |
|
Serotonin Antagonists |
|
|
|
|
|
33 |
|
Antidepressive Agents |
|
|
|
|
|
34 |
|
Serotonin 5-HT1 Receptor Agonists |
|
|
|
|
|
35 |
|
Serotonin Receptor Agonists |
|
|
|
|
|
36 |
|
Serotonin Agents |
|
|
|
|
|
37 |
|
Dopamine Antagonists |
|
|
|
|
|
38 |
|
Antipsychotic Agents |
|
|
|
|
|
39 |
|
Psychotropic Drugs |
|
|
|
|
|
40 |
|
Dopamine agonists |
|
|
|
|
|
41 |
|
Dopamine D2 Receptor Antagonists |
|
|
|
|
|
42 |
|
Serotonin |
Investigational, Nutraceutical |
|
|
50-67-9 |
5202
|
Synonyms:
3-(2-Aminoethyl)-1H-indol-5-ol
3-(2-Aminoethyl)indol-5-ol
3-(b-Aminoethyl)-5-hydroxyindole
5 Hydroxytryptamine
5-HT
5-HTA
5-Hydroxy-3-(b-aminoethyl)indole
5-Hydroxyltryptamine
5-Hydroxytriptamine
5-Hydroxytryptamine
5-Hydroxy-tryptamine
Antemovis
|
DS Substance
Enteramin
Enteramine
Hippophaine
Hydroxytryptamine
Serotonine
sérotonine
thrombocytin
Thrombocytin
thrombotonin
Thrombotonin
|
|
Interventional clinical trials:
(show all 23)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Assessment in Early Changes in the Parameters of Optical Coherence Tomography (OCT Spectral Domain) in Patients With Subfoveal Neovascular Membranes Related to Age After Treatment With a Single Intravitreal Injection of Lucentis. |
Unknown status |
NCT01669447
|
Phase 4 |
|
2 |
A Phase I/II Study of the NT-501 Intraocular Implant Releasing Ciliary Neurotrophic Factor (CNTF) in Participants With CNGB3 Achromatopsia |
Completed |
NCT01648452
|
Phase 1, Phase 2 |
|
3 |
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of AGTC 402, a Recombinant Adeno-associated Virus Vector Expressing CNGA3, in Patients With Congenital Achromatopsia Caused by Mutations in the CNGA3 Gene |
Recruiting |
NCT02935517
|
Phase 1, Phase 2 |
|
4 |
An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hCARp.hCNGB3) for Gene Therapy of Adults and Children With Achromatopsia Owing to Defects in CNGB3 |
Recruiting |
NCT03001310
|
Phase 1, Phase 2 |
|
5 |
An Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector (AAV2/8-hG1.7p.coCNGA3) for Gene Therapy of Children With Achromatopsia Owing to Defects in CNGA3 |
Recruiting |
NCT03758404
|
Phase 1, Phase 2 |
|
6 |
Long-term Follow-up Study of Participants Following an Open Label, Multi-centre, Phase I/II Dose Escalation Trial of a Recombinant Adeno-associated Virus Vector for Gene Therapy of Adults and Children With Achromatopsia Owing to Defects in CNGB3 |
Recruiting |
NCT03278873
|
Phase 1, Phase 2 |
|
7 |
A Multiple-Site, Phase 1/2, Safety and Efficacy Trial of a Recombinant Adeno-associated Virus Vector Expressing CNGB3 (rAAV2tYF-PR1.7-hCNGB3) in Patients With Congenital Achromatopsia Caused by Mutations in the CNGB3 Gene |
Recruiting |
NCT02599922
|
Phase 1, Phase 2 |
|
8 |
Safety and Efficacy of a Single Subretinal Injection of rAAV.hCNGA3 in Patients With CNGA3-linked Achromatopsia Investigated in an Exploratory, Dose-escalation Trial |
Active, not recruiting |
NCT02610582
|
Phase 1, Phase 2 |
rAAV.hCNGA3 |
9 |
Effect of Clemastine Fumarate on Color Vision in Healthy Controls |
Completed |
NCT02613091
|
Phase 1 |
Clemastine fumarate |
10 |
Evaluating Color Perception Under LED Red/Green and Green Dominant Light |
Completed |
NCT01927536
|
|
|
11 |
Prevalence and Severity of Colour Vision Deficiency Among Turkish Children |
Completed |
NCT04048499
|
|
|
12 |
Clinical and Genetic Characterization of Individuals With Achromatopsia |
Completed |
NCT01846052
|
|
|
13 |
Predictive Effect of Ganglion Cell Layer on Visual Acuity at 6 Months and on Visual Function at 1 Year After an Episode of Optic Neuritis |
Completed |
NCT02864134
|
|
|
14 |
Visual Activity Evoked by Infrared in Humans After Dark Adaptation |
Completed |
NCT02909985
|
|
|
15 |
Evning Exposure to Computer Screen Disrupts Sleep, Attention and Biological Rhythms |
Completed |
NCT02957383
|
|
|
16 |
Biomarker for Duchenne Disease AN INTERNATIONAL, MULTICENTER, EPIDEMIOLOGICAL PROTOCOL |
Recruiting |
NCT02994030
|
|
|
17 |
Foundation Fighting Blindness Registry, My Retina Tracker |
Recruiting |
NCT02435940
|
|
|
18 |
Anthropogenetic Variability in the Group of Individuals With Febrile Seizures Population Genetic Study |
Recruiting |
NCT03481764
|
|
|
19 |
Demonstrating Feasibility of Color Vision Deficient Provider Use of EnChroma Products in the Emergency Department |
Not yet recruiting |
NCT04021914
|
|
|
20 |
Evaluation of Glycerol Phenylbutyrate (PBA) Use in Endoplasmic Reticulum Stress Reduction in ATF6-/- Patients |
Not yet recruiting |
NCT04041232
|
Early Phase 1 |
PBA |
21 |
Investigation of the Effect of Protanopia ("Red Blindness") on the Brightness Perception of Brake Lights and Their Effect on Reaction Time |
Not yet recruiting |
NCT04060238
|
|
|
22 |
Examining the Neural Bases of Early Visual and Auditory Processing and Emotion Recognition Deficits in Schizophrenia Using Magnetoencephalography |
Not yet recruiting |
NCT02588014
|
|
|
23 |
Aripiprazole Effects on Reward Processing in Deficit Syndrome Schizophrenia |
Terminated |
NCT00209027
|
|
Aripiprazole |
|